Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Allergan Q3 2009 Earnings Call Transcript
- Question-and-Answer SessionOperator Thank you. Operator Instructions. Our first question comes from Frank Pinkerton, SunTrust. Frank Pinkerton - SunTrust Robinson Humphrey Hey. First of all, Dave I believe you made a comment around Dysport expanding the market versus cannibalizing it. Do you have any data point that Jim gave us...
- Earnings calls 2009-10-29
Additional Resources
- ADVANCE/Glaucoma Foundation Launches Internet Campaign Against "Silent Thief of Sight; Web Site Unveiling Marks National Glaucoma Awareness Week
- NEW YORK--BUSINESS WIRE--Jan. 20, 1996--The Glaucoma Foundation announced today that it has established a site on the Internet's World Wide Web as part of its campaign against glaucoma, the leading preventable cause of blindness. Glaucoma affects more than 50,000,000 people worldwide. The web site, which provides access to...
- Research articles 1996-01-16
- Experts hope Asian glaucoma guidelines will prevent blindness for millions
- HONG KONG AFP ? The first ever set of guidelines for specifically diagnosing and treating glaucoma in Asians has been developed, a leading eye doctor said, in a move medics hope will prevent millions being blinded by the eye disease. Dr Ivan Goldberg, president of the South East Asia...
- Research articles 2003-11-28
- SOLX Initiates Glaucoma Clinical Trials for the DeepLight® Gold Micro-Shunt; First Glaucoma Device to Lower Intraocular Pressure without a Bleb
- BOSTON -- SOLX, Inc. today announced Investigational Device Exemption IDE approval from the U.S. Food & Drug Administration FDA to begin studies of the DeepLight Gold Micro-Shunt GMS implant for glaucoma. This randomized, multi-center study will evaluate safety and efficacy of the GMS for lowering intraocular pressure IOP in primary...
- Research articles 2005-10-18
- -U.S. HHS: Blacks, whites benefit from different surgical glaucoma treatments
- M2 PRESSWIRE-6 July 1998-U.S. HHS: Blacks, whites benefit from different surgical glaucoma treatments C1994-98 M2 COMMUNICATIONS LTD RDATE:060798 Researchers supported by the National Institutes of Health have discovered that black and white patients with advanced glaucoma respond differently to two surgical treatments for the disease. A...
- Research articles 1998-07-06
- Anecortave Acetate Clinical Trial Data for Glaucoma Presented at World Congress of Glaucoma
- SINGAPORE -- Alcon, Inc. (NYSE: ACL) released today the three-month interim results of the first controlled clinical study of anecortave acetate administered as an anterior juxtascleral depot in the sub-Tenon's space to reduce intraocular pressure in patients with open-angle glaucoma. The data were presented in a poster at the World...
- Research articles 2007-07-18
- Glaucoma could turn 8.4 million Asians blind by 2010: survey
- HONG KONG AFP — More than 8.4 million people in Asia will turn blind from glaucoma by 2010 if they do not undergo timely treatment, a region-wide survey released on Monday showed. Glaucoma, irreversible damage on the optic nerve caused by high pressure within the eyeball, was the world's...
- Research articles 2008-06-30
- Glaucoma treatment by laser spurs spectacular rise of Ellex.
- Apr 24, 2002 The Age ABIX via COMTEX -- The three main causes of blindness are cataracts, glaucoma and retinal therapy. An Australian company, Ellex Medical Lasers, is tackling them all. The company's managing director, Peter Rowland, says that glaucoma is a new field...
- Research articles 2002-04-24
- Laser Diagnostic Technologies Ships 2,500th Glaucoma Detection Instrument; Marketplace Milestone Supports Technology
- Business Editors & Health/Medical Writers SAN DIEGO--BUSINESS WIRE--Aug. 13, 2002 Laser Diagnostic Technologies, developers of the GDx -- the unique and essential technology for detecting and tracking glaucoma by measuring the retinal nerve fiber layer, the tissue affected by glaucoma -- today announced that the company has shipped...
- Research articles 2002-08-13
- SOLX Introduces DeepLight Glaucoma Treatment System; First Combination Laser and Photo-Titratable Gold Micro-Shunt Therapy in Development at Boston University Photonics Center
- BOSTON -- SOLX, Inc. will share its vision of a new glaucoma treatment system at this week's American Society of Cataract and Refractive Surgery ASCRS annual symposium at the Washington Convention Center in Washington, D.C. The DeepLightR Glaucoma Treatment System is the first of its kind to combine a Titanium...
- Research articles 2005-04-11
- Aging Population Spurs AMD and Glaucoma Research. (Investments In Sight).(age-related macular degeneration)(Brief Article)
- Glaucoma affects 67 million people worldwide and 1% to 2% of Americans, especially after age 60. It is the second leading cause of blindness in Caucasians and the leading cause in people of African descent. There is no cure for most forms, but it can Glaucoma...
- Research articles 2001-12-22
- ACETO Corp. (Pharmaceuticals in Brief).(glaucoma drug approval)(Brief Article)
- ACETO Corp. announced one of its customers has received Food and Drug Administration FDA approval for its abbreviated new drug application ANDA for a generic drug for treating glaucoma The company is the sole supplier of the active pharmaceutic ACETO Corp. announced one of...
- Research articles 2003-06-09
- Allergan offers glaucoma advice
- ALLERGAN, in a joint effort with Webb-Patterson Communications, is running an educational campaign designed to raise awareness of glaucoma and, in turn, drive sales of its Lumigan and Alphagan glaucoma treatments.
- Research articles 2003-06-01
- Alcon Presents Clinical Trial Data on Anecortave Acetate for Glaucoma
- WASHINGTON -- Alcon, Inc. (NYSE: ACL) released today the primary efficacy and safety results of the second controlled proof of concept clinical study of anecortave acetate administered as an anterior juxtascleral depot in the sub-Tenon's space to reduce intraocular pressure in patients with open-angle glaucoma. These initial data were presented...
- Research articles 2008-03-07
- Allergan Announces FDA Approval of LUMIGAN® as First-Line Treatment for Elevated Eye Pressure in Open-Angle Glaucoma; Indication Expands Approved Uses of LUMIGAN® in the Management of Glaucoma
- IRVINE, Calif. -- Allergan, Inc. (NYSE:AGN) today announced that the United States Food and Drug Administration FDA has approved Allergan's once-daily prescription eye drop LUMIGANR bimatoprost ophthalmic solution 0.03% as a first-line treatment for elevated intraocular pressure IOP associated with open-angle glaucoma or ocular hypertension. The LUMIGANR first-line indication is...
- Research articles 2006-06-23
- Heavy computer use linked to glaucoma: study
- PARIS AFP — Heavy users of computers, especially those who are short-sighted, may be at risk from glaucoma, a disease that can cause blindness, a study published in a specialist journal on Tuesday says. Japanese doctors assessed the sight of more than 10,200 Japanese workers, measuring them for visual...
- Research articles 2004-11-15
- Seeing Machines wins major industry awards for glaucoma project.
- M2 PRESSWIRE-10 April 2006-Seeing Machines Limited: Seeing Machines wins major industry awards for glaucoma projectC1994-2006 M2 COMMUNICATIONS LTD RDATE:10042006 Seeing Machines (AIM:SEE) was awarded two iAwards at the AIIA's gala presentation dinner last Friday night (7 April) for its glaucoma...
- Research articles 2006-04-10
- UTEK Transfers a Worldwide License for a New Treatment of Glaucoma to Advanced Refractive Technologies
- TAMPA, Fla. & SAN CLEMENTE, Calif. -- UTEK Corporation (AMEX:UTK) (LSE-AIM:UTK), a specialty finance company focused on technology transfer, and Advanced Refractive Technologies, Inc. (OTCBB:ARFR), a medical device company focused on the development and marketing of innovative ophthalmic applications, announced today that Advanced Refractive Technologies has acquired Advanced Glaucoma Technologies,...
- Research articles 2006-08-11
- La Jolla Diagnostics Inc. plans to market treatment for glaucoma
- LA JOLLA, Calif.--BUSINESS WIRE--Feb. 12, 1996--La Jolla Diagnostics Inc., a company engaged in the development and marketing of diagnostic and consumer health care products, (NASDAQ BB OTC:LAJD) announced Monday that it plans to market a treatment for open angle Glaucoma.Glaucoma is a condition of the eye in which there is...
- Research articles 1996-02-12
- New glaucoma screening technology unveiled
- NEW YORK--BUSINESS WIRE--March 6, 1997--Welch Allyn, a world leader in the manufacture of medical diagnostic instruments, today introduced a new glaucoma screening technology offering faster and more effective testing results. The technology, called Frequency Doubling Perimetry FDP, is designed to detect and diagnose early visual loss in glaucoma and...
- Research articles 1997-03-06
- << Previous
- page 1 of 1
- Next >>
Presented by American Express